An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 208 participants.
Also called NCT01151410
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 208 participants
- Sponsor
- Registry
-
NCT01151410 -
2009-017029-20
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Guatemala, Hungary, Poland, Puerto Rico, Slovakia, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT01151410. Randomized; double masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2015-08 (actual). Results posted on 2016-03-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
- Condition
- Hypertension
- Intervention (Drug)
- Aliskiren
- Intervention (Drug)
- Enalapril
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01151410- Content hash
3ed130a527fa7bf436109c17c649cc027e02730ed844b15c1299e06d36f006b0